Esperion Therapeutics, Inc. ESPR was a big mover last session, as its shares rose above 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up almost 68% in the past one-month time frame.
Over the last 30 days, the company has seen two negative estimate revisions and its Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday's move higher can last.
Esperion Therapeutics currently carries a Zacks Rank #3 (Hold).
Esperion Therapeutics, Inc. Price
Esperion Therapeutics, Inc. Price | Esperion Therapeutics, Inc. Quote
A better-ranked stock in the Medical - Drugs space is Grifols, S.A. GRFS, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ESPR going up? Or down? Predict to see what others think: Up or Down
8 Stocks with Huge Profit Potential
Just released: Driverless Cars: Your Roadmap to Mega-Profits Today. In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Esperion Therapeutics, Inc. (ESPR): Free Stock Analysis Report
Grifols, S.A. (GRFS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research